Back to Cover
Dossier Archive
BioBusiness & Venture Capital
M&A deal flow, ADC licensing, clinical trial readouts, and biotechnology financing markets.
SHOWING 2 INVESTIGATIONS IN THIS ARCHIVESORT: LATEST READOUTS
BioBusinessLab to Launch
Oct 26, 2026•5 min read
The Q3 BioCapital Report: $14B Deployed into Next-Gen Conjugates and Degitizers
An exclusive breakdown of global life science venture allocations, private valuations, and the reopening of the public biotech IPO window.
BioBusinessIn the Pipeline
Oct 20, 2026•7 min read
Beyond Semaglutide: The Next-Gen Incretin Wave and Muscle-Preserving Peptides
Weight loss is no longer the clinical challenge—preserving lean skeletal muscle and metabolic rate is. The clinical pipeline of multi-receptor peptides is redefining obesity pharmacotherapy.